Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2003
[Evaluation of efficacy of 153Sm-EDTMP in patients with painful bone metastases of breast cancer].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Haiming, Tan Tianzhi, Fang Ling, Zhang Xiying
Аннотация
OBJECTIVE: To explore the therapeutic efficacy of 153Sm-EDTMP in treating painful bone metastases from breast cancer.
METHODS: Seventy-six patients with painful bone metastases from breast cancer entered the study and were treated by intravenous administration of 153Sm-EDTMP in two doses.
RESULTS: Overall, 65 of 76 patients (85.52%) experienced prompt pain relief; among them 25 patients (32.89%) felt complete remission and 40 patients (52.63%) met with moderate remission. Follow-up imaging examinations were performed after each course of treatment. Complete metastatic foci disappearance was achieved in 6 cases and partial metastatic foci disappearance or regression was achieved in 16 cases, so the global effective rate was 28.95%. No major adverse effects were observed, and hematological toxicity did not exceed grade 3 in accordance to the World Health Organization criteria.
CONCLUSION: 153Sm-EDTMP is safe and effective for fast palliation of painful bone metastases and for inhibition of metastatic foci from breast cancer.
METHODS: Seventy-six patients with painful bone metastases from breast cancer entered the study and were treated by intravenous administration of 153Sm-EDTMP in two doses.
RESULTS: Overall, 65 of 76 patients (85.52%) experienced prompt pain relief; among them 25 patients (32.89%) felt complete remission and 40 patients (52.63%) met with moderate remission. Follow-up imaging examinations were performed after each course of treatment. Complete metastatic foci disappearance was achieved in 6 cases and partial metastatic foci disappearance or regression was achieved in 16 cases, so the global effective rate was 28.95%. No major adverse effects were observed, and hematological toxicity did not exceed grade 3 in accordance to the World Health Organization criteria.
CONCLUSION: 153Sm-EDTMP is safe and effective for fast palliation of painful bone metastases and for inhibition of metastatic foci from breast cancer.